Faculty of Medicine, Research Unit of Clinical Medicine, Psychiatry, University of Oulu.
Oulu University Hospital, Psychiatry, Oulu, Finland.
Int Clin Psychopharmacol. 2023 May 1;38(3):146-153. doi: 10.1097/YIC.0000000000000441. Epub 2022 Nov 11.
We investigated factors associated with benzodiazepine (BZD) use during late adolescence and early adulthood. The study population consisted of 508 adolescents admitted to psychiatric inpatient care between April 2001 and March 2006. Information on adolescents' family- and school-related factors, suicidality and psychiatric disorders were obtained by semistructured interviews. Data on BZD prescriptions from 1999 to 2012 were collected from the Social Insurance Institution of Finland. In males heavy BZD use associated with adolescent substance-use disorder (OR, 3.5; P < 0.004) and parents' psychiatric problems (OR, 3.5; P = 0.029). Among females, conduct disorder (OR, 3.3; P = 0.016), being a bully/bully-victim (OR, 3.3; P = 0.019) and parental substance-use problems (OR, 2.6; P = 0.024) were related to heavy BZD use. The mean (±SD) age of first BZD prescription was significantly lower in heavy, compared with mild users (men: 19.3 ± 2.5 vs. 21.0 ± 2.5 years, P = 0.027; women: 19.7 ± 2.6 vs. 21.5 ± 3.4 years, P = 0.027). Heavy, compared with mild, BZD use is associated with female suicide attempts (OR, 5.0; P = 0.049). Physicians should be cautious when prescribing BZDs to young adults and must allocate treatment to those with carefully evaluated clinical indications.
我们研究了与青少年晚期和成年早期使用苯二氮䓬类药物(BZD)相关的因素。该研究人群由 2001 年 4 月至 2006 年 3 月期间住院的 508 名青少年组成。通过半结构化访谈获得了青少年家庭和学校相关因素、自杀意念和精神障碍的信息。从芬兰社会保险机构收集了 1999 年至 2012 年 BZD 处方的数据。在男性中,重度 BZD 使用与青少年物质使用障碍(OR,3.5;P <0.004)和父母的精神问题(OR,3.5;P = 0.029)相关。在女性中,品行障碍(OR,3.3;P = 0.016)、欺凌/被欺凌者(OR,3.3;P = 0.019)和父母的物质使用问题(OR,2.6;P = 0.024)与重度 BZD 使用相关。与轻度使用者相比,首次 BZD 处方的平均(±SD)年龄显著较低(男性:19.3 ± 2.5 岁 vs. 21.0 ± 2.5 岁,P = 0.027;女性:19.7 ± 2.6 岁 vs. 21.5 ± 3.4 岁,P = 0.027)。与轻度 BZD 使用相比,重度 BZD 使用与女性自杀企图相关(OR,5.0;P = 0.049)。医生在为年轻成年人开 BZD 处方时应谨慎,并必须将治疗分配给那些经过仔细评估临床指征的患者。